New Research Grant For Deoxymabs in Metastatic Breast Cancer (Patrys)
Posted: 26 August 2022 Today Patrys announced that the Olivia Newton-John Cancer Research Institute (ONJCRI) has been awarded a $100,000 Victorian State Government Victorian Medical Research Acceleration Fund (VMRAF) grant to support its research investigating the potential for PAT-DX1…
Have your say into a new scale-up and manufacturing facility for biotech and medtech companies
Posted: 25 August 2022 Closing date: 31 August 2022 Translational Manufacturing@TRI (TM@TRI) will serve as Australia’s first purpose built biomedical translational manufacturing facility that will enable biotech and medtech start-up companies to move to the scale-up stage. Construction…
BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
Posted: 24 August 2022 The Directors of Biotron Limited (‘Biotron’ or ‘the Company’) are pleased to advise that a Phase 2 HIV-1 clinical trial (BIT225-010; ACTRN12621000937819) of its lead antiviral drug, BIT225, is fully recruited. The trial, which…
CLARITY 2.0 COVID-19 Study Concludes Recruitment
Posted: 18 August 2022 Dimerix Limited (ASX: DXB) a biopharmaceutical company with Phase 3 clinical studies in inflammatory diseases currently underway, today confirmed that the CLARITY 2.0 led study of COVID-19 patients has concluded recruitment to allow this…
Global Talent Visa and Victorian State Nomination Program
Posted: 16 August 2022 Access to skilled talent within the sector remains a significant challenge. Last year BioMelbourne Network participated in discussions with the Federal Global Business & Talent Attraction Taskforce and the availability of their Global Talent…
Biotech companies buck trend that says sector moves slowly
Posted: 15 August 2022 Patience pays off in the biotech world, but the June quarter was pretty fast-moving for a clutch of Australian companies as trials yielded results, patents and manufacturing deals were inked and the odd acquisition…
A reconstructive innovation is giving skin cancer patients another option
Posted: 11 August 2022 PolyNovo Biomaterials Ltd. are delighted to share a new article published as part of the #YourSkin2022 campaign that discusses the innovative application of #NovoSorbBTM for skin cancer patients with complex reconstructive needs. A synthetic dermal…
CSIRO, opens a new lab that will supercharge Australia’s ability to produce vaccines and therapeutics locally
Posted: 11 August 2022 CSIRO, Australia’s national science agency, has opened a new $23.1 million national lab in Melbourne that will bolster the nation’s ability to produce vaccines and drug treatments onshore. Researchers at CSIRO’s National Vaccine and…
Research Australia’s Global Landscape Analysis of Childhood Dementia Research
Posted: 10 August 2022 Research Australia is pleased to partner with the Childhood Dementia Initiative to report on global childhood dementia clinical research: Childhood Dementia Global Landscape Analysis. Research Australia’s report identifies high value-research investment opportunities and emerging…
Genesis Capital invests in Australian firm Crux Biolabs
Posted: 9 August 2022 Genesis Capital is partnering with existing management to expand Crux into new testing and clinical trial streams. Crux Biolabs, a leading Australian laboratory for vaccines, immunotherapies, immuno-oncology and infectious diseases, has announced a significant…
Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
Posted: 8 August 2022 Neuren Pharmaceuticals (ASX: NEU) today announced that its Phase 2 clinical trials of NNZ-2591 in children with each of Phelan-McDermid syndrome (PMS) and Pitt Hopkins syndrome (PTHS) are open for enrolment. The first subjects…
Burnet teams up with Monash and BioCurate to develop novel HIV antivirals
Posted: 4 August 2022 Burnet Institute, in collaboration with Monash Institute of Pharmaceutical Sciences (MIPS) has received Proof of Concept funding from BioCurate to develop next-generation human immunodeficiency virus (HIV) antivirals. The multi-disciplinary research team, led jointly by…
